We are developing a novel, oral, investigational product (NRTK-001) for the treatment of PTSD (Post Traumatic Stress Disorder). NRTK-001 utilizes the body's own cannabinoid system to enhance reduced cannabinoid function in PTSD. The first Phase was successfully completed. We are raising $10,674.400 USD to complete Phases II and III to obtain FDA approval and to produce the first specific medicine to cure PTSD. https://neuritek.com https://antibiostress.com